Humacyte/HUMA

$7.30

1.25%
-
1D1W1MYTD1YMAX

About Humacyte

Humacyte, Inc. is engaged in the development and manufacturing of off-the-shelf, universally implantable, bioengineered human tissues. The Company is engaged in developing a portfolio of human acellular vessels (HAVs) with varying diameters and lengths. The HAV cabinet would initially target the vascular repair, reconstruction, and replacement market, including vascular trauma; atrioventricular (AV) access for hemodialysis; peripheral arterial disease (PAD); and coronary artery bypass grafting (CABG). The Company has developed a novel paradigm for manufacturing human tissues that are intended to mimic key aspects of human physiology. It is also engaged in developing its HAVs for pediatric heart surgery and the delivery of cellular therapies, including pancreatic islet cell transplantation to treat Type 1 diabetes. The Company’s scientific technology platform uses primary human aortic vascular cells from a working cell stock, isolated from donor tissues and cryopreserved.

Ticker

HUMA

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

Laura Niklason

Employees

183

Headquarters

Durham, United States

Humacyte Metrics

BasicAdvanced
$837M
Market cap
-
P/E ratio
-$1.01
EPS
1.63
Beta
-
Dividend rate
$837M
1.62539
$7.46
$1.96
1.7M
8.371
60.607
70.79
-61.5%
-61.38%
-195.68%
-68.92%
32.011
32.011
-100%
-254.12%

What the Analysts think about Humacyte

Analyst Ratings

Majority rating from 6 analysts.
Buy

Price Targets

Average projection from 6 analysts.
9.59% upside
High $15.00
Low $6.00
$7.30
Current price
$8.00
Average price target

Humacyte Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
0% profit margin
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$0
NaN%
Net income
-$32M
26.69%
Profit margin
0%
NaN%

Humacyte Earnings Performance

Earnings per share (EPS)

Company profitability
Missed by 28.89%
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$0.22
-$0.25
-$0.24
-$0.29
-
Expected
-$0.22
-$0.25
-$0.24
-$0.23
-$0.24
Surprise
0.15%
-1.32%
-1.98%
28.89%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

FAQs

What’s the current market cap for Humacyte stock?

Humacyte (HUMA) has a market cap of $859M as of May 25, 2024.

What is the P/E ratio for Humacyte stock?

The price to earnings (P/E) ratio for Humacyte (HUMA) stock is 0 as of May 25, 2024.

Does Humacyte stock pay dividends?

No, Humacyte (HUMA) stock does not pay dividends to its shareholders as of May 25, 2024.

When is the next Humacyte dividend payment date?

Humacyte (HUMA) stock does not pay dividends to its shareholders.

What is the beta indicator for Humacyte?

Humacyte (HUMA) has a beta rating of 1.57. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.

What is the Humacyte stock price target?

The target price for Humacyte (HUMA) stock is $8, which is 11.89% above the current price of $7.15. This is an average based on projections from 6 analysts, and represents their view of what the stock price could be in 12 or 18 months. This should not be seen as investment advice - Lightyear does not carry out investment research.

Buy or sell Humacyte stock

Buy or sell Humacyte stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing